Patents Issued in April 3, 2018
  • Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof
    Patent number: 9932327
    Abstract: The present invention relates to the rohitukine (5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-4H-chromen-4-ones) analogs of formula A and pharmaceutically acceptable salts thereof. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various proliferative disorders such as melanoma, leukemia, breast cancer and prostate cancer etc. [insert Formula A here] wherein, n=0 or 1, when n=1, the dotted line indicates the double bond.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 3, 2018
    Assignee: The Council of Scientific & Industrial Research
    Inventors: Ram A. Vishwakarma, Sandip B. Bharate, Shashi Bhushan, Dilip M. Mondhe, Shreyans K. Jain, Samdarshi Meena, Santosh K. Guru, Anup S. Pathania, Suresh Kumar, Akanksha Behl, Mubashir J. Mintoo, Sonali S. Bharate, Prashant Joshi
  • 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors
    Patent number: 9932328
    Abstract: Compound of formula (I) wherein: R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or ?O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: April 3, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Anne Marie Jeanne Bouillot, Alexis Denis, Ann Louise Walker, John Liddle
  • Benzimidazole derivatives as RLK and ITK inhibitors
    Patent number: 9932329
    Abstract: The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: April 3, 2018
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Timothy Owens, Ronald J. Hill
  • Piperazine derivatives for treating disorders
    Patent number: 9932330
    Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: April 3, 2018
    Assignees: The University of Nottingham, NewSouth Innovations PTY Limited
    Inventors: David Bates, Jonathan Morris
  • Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
    Patent number: 9932331
    Abstract: The present invention provides a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof which has an excellent NHE3 inhibitory effect: A-Y??[1] wherein A represents a structure represented by the following formula [2]: wherein R11 and R12 each represent a halogen atom or others as described herein, R2 represents C1-6 alkyl or others as described herein, ring E represents triazole, tetrazole, pyrimidine, or others as described herein, R31 and R32 each represent a hydrogen atom, C1-6 alkyl, C1-6 alkoxy, or others as described herein, and W represents a single bond, the formula —NH—, the formula —O—, or the formula —CONH—, and Y represents a hydrogen atom or a structure selected from
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: April 3, 2018
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Shoichi Kuroda, Kenichi Kawabe, Yasunobu Ushiki, Hiroshi Ohta, Fumito Uneuchi, Tsuyoshi Shibata, Hideaki Tabuse, Eiji Munetomo, Sumi Chonan
  • FXR (NR1H4) modulating compounds
    Patent number: 9932332
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: April 3, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Christian Gege
  • Benzothiazole compound and medicine containing same
    Patent number: 9932333
    Abstract: It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A? peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R1 represents an optionally substituted hydrocarbon group; R2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R2 and R4 optionally together form an alkylene group; and R5 represents an anion.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 3, 2018
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Atsuhiko Taniguchi, Yusuke Shimizu
  • Tetrahydroimidazopyridine derivatives as modulators of TNF activity
    Patent number: 9932334
    Abstract: A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Pyrrolopyridine or pyrazolopyridine derivatives
    Patent number: 9932335
    Abstract: The present invention relates to compounds of formula wherein R1, Y1, Y2, X, R and n are as defined herein.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 3, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Theresa Maria Ballard, Emmanuel Pinard, Herve Schaffhauser, Katrin Groebke Zbinden, Thomas Ryckmans, Alexander Flohr
  • Process for the preparation of apixaban and intermediates thereof
    Patent number: 9932336
    Abstract: The present invention relates to an improved process for the preparation of Apixaban and intermediates thereof. Further the present invention also relates to novel intermediate of Formula V and its process for the preparation.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 3, 2018
    Assignee: JUBILANT GENERICS LIMITED
    Inventors: Khushwant Singh, Amit Kumar Srivastava, Ratnakar Tripathi, Jai Prakash Verma, Dharam Vir, Lalit Kumar, Mukesh Masand, Rajendra Singh Shekhawat, Rakesh Tiwari, Sujay Biswas
  • Method for the production of Praziquantel and precursors thereof
    Patent number: 9932337
    Abstract: The present invention relates to methods for the production of enantiopure or enantioenriched Praziquantel precursors and to methods for the production of enantiopure or enantioenriched Praziquantel comprising the methods for the production of the Praziquantel precursors. The present invention further relates to compounds or intermediates useful in such methods.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: David Maillard, Andreas Waechtler, Jeremy Maurin, Ewgenij Wakaresko, Christian Jasper
  • Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
    Patent number: 9932338
    Abstract: Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: April 3, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Laura Carzaniga, Fabio Rancati, Andrea Rizzi, Ian Linney
  • Helquats with heteroaromatic substituents, preparation thereof, and use thereof as G-quadruplex stabilizers
    Patent number: 9932339
    Abstract: Helquat derivatives of general formula I, in which substituents R1 and R2 are independently selected from a group comprising H and C1 to C4 alkyl, up to three of S1,2, S1?,2?, S3,4 and S3?,4? are present, each of S1,2, S1?,2?, S3,4 and S3?,4? independently represents a linker consisting of a bivalent hydrocarbon chain having 3-6 carbon atoms, preferably hydrocarbon chain having 4 carbon atoms, and one to four atoms selected from the carbon atoms with the descriptor 2, 4, 2?, and 4? are substituted with a substituent R3 of general formula II, wherein R4 is substituted or unsubstituted heteroaryl, T1 and T2 are independent linkers that bridge atoms N5 with C8 and N5? with C8?, wherein T1 and T2 independently represent a bivalent hydrocarbon chain having 2-5 carbon atoms, preferably 2 or 3 carbon atoms; and anions (X1)? and (X2)? independently represent anions of pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: April 3, 2018
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE
    Inventors: Filip Teply, Miroslav Hajek, Erika Kuzmova, Jaroslav Kozak, Veronika Komarkova, Pavla Hubalkova, Paul Eduardo Reyes-Gutierrez, Michael Jirasek, Manoj R. Sonawane, Vishwas D. Joshi, Lukas Severa, Jana Novotna
  • Substituted indoles
    Patent number: 9932340
    Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: April 3, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, William McClellan, Mike Michaelides, Ramzi Sweis, Noel Wilson, Justin Dietrich
  • Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
    Patent number: 9932341
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 3, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
  • Imidazopyrimidine derivatives as modulators of TNF activity
    Patent number: 9932342
    Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Fused tricyclic benzimidazoles derivatives as modulators of TNF activity
    Patent number: 9932343
    Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
    Patent number: 9932344
    Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: April 3, 2018
    Assignees: Cancer Research Technology Limited, Imperial Innovations Limited, Emory University
    Inventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
  • Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors
    Patent number: 9932345
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 3, 2018
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Pyrrolopyrimidines for use in influenza virus infection
    Patent number: 9932346
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: April 3, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Tim Hugo Maria Jonckers, David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Constant Johan Embrechts, Jérôme Émile Georges Guillemont
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9932347
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 3, 2018
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Process for improved oxycodone synthesis
    Patent number: 9932348
    Abstract: Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: April 3, 2018
    Assignee: RHODES TECHNOLOGIES
    Inventors: Joshua Robert Giguere, Keith Edward McCarthy, Marcel Schleusner
  • 8-carboxamido-2,6-methano-3-benzazocines
    Patent number: 9932349
    Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH2—OH, —CH2NH2, —NHSO2CH3, and Y is O, S or NOH are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. 8-Carboxamides, thiocarboxamides, hydroxyamidines and formamides are preferred.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: April 3, 2018
    Assignee: Rensselaer Polytechnic Institute
    Inventor: Mark P. Wentland
  • Inhibitors of IRAK4 activity
    Patent number: 9932350
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith
  • Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
    Patent number: 9932351
    Abstract: The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R5, R5?, X1, X2, n, and m are described herein.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: April 3, 2018
    Assignee: Forma Therapeutics, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, David Lancia, Jr.
  • Compounds for the treatment of ischemia-reperfusion-related diseases
    Patent number: 9932352
    Abstract: The present invention relates to compounds of formula (I) useful in the treatment of ischemia-reperfusion-related pathologies.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: April 3, 2018
    Assignee: MINERVA PATENTS S.A.
    Inventors: Antonio Guarna, Federico Cozzolino
  • Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 9932353
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: April 3, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: B. Narasimhulu Naidu, Manoj Patel
  • Imidazo-oxadiazole and imidazo-thiadiazole derivatives
    Patent number: 9932354
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: April 3, 2018
    Assignee: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivatives and use thereof
    Patent number: 9932355
    Abstract: Provided are a pharmaceutical composition containing a 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivative represented by Formula 1 as an active ingredient and a use thereof effective on a vascular inflammation-related infectious disease triggered by activity of HMGB1 protein. As investigating an anti-sepsis effect through a CLP-induced sepsis animal test that a sepsis survival rate is increased, it is identified that the pharmaceutical composition contains the 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivative or a pharmaceutically available salt thereof as an active ingredient to be used as a therapeutic agent for a vascular inflammatory disease and infectious disease including sepsis triggered by activity of HMGB1 protein.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: April 3, 2018
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Taeho Lee, Jong-Sup Bae, Kyung-Sik Song, Sangkyu Lee, Kwang-Hyeon Liu, Wonhwa Lee, Doohyun Lee
  • Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 9932356
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: April 3, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: John F. Kadow, David R. Langley, B. Narasimhulu Naidu, Kevin Peese, Zhongyu Wang
  • Synthetic method of fused heteroaromatic compound and fused heteroaromatic compound and intermediate therefor
    Patent number: 9932357
    Abstract: A synthetic method of a fused heteroaromatic compound includes preparing a first intermediate represented by Chemical Formula 1, obtaining a second intermediate by reacting the first intermediate and an aldehyde compound, obtain a third intermediate by performing deprotection and reduction reactions on the second intermediate, and obtaining a fused heteroaromatic compound by performing a cyclization reaction on the third intermediate.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: April 3, 2018
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Don-Wook Lee, Jeong Il Park, Eigo Miyazaki
  • Energy storage molecular material, crystal dielectric layer and capacitor
    Patent number: 9932358
    Abstract: The present disclosure provides an energy storage molecular material, crystal dielectric layer and capacitor which may solve a problem of the further increase of volumetric and mass density of reserved energy associated with some energy storage devices, and at the same time reduce cost of materials.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: April 3, 2018
    Assignee: CAPACITOR SCIENCE INCORPORATED
    Inventor: Pavel Ivan Lazarev
  • Organic electroluminescent materials and devices
    Patent number: 9932359
    Abstract: A compound having a structure according to wherein Y is a carbene moeity coordinated to a trivalent copper atom Cu is disclosed. In Formula I, L1, L2, and L3 are three monodentate ligands. In Formula II, L1, L2, and L3 represent a single tridentate ligand chelated by X, wherein X is B—H, C—H, N, P, or P?O.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: April 3, 2018
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Mark E. Thompson, Rasha Hamze, Peter I. Djurovich
  • Qualitative and quantitative point-of-care assays
    Patent number: 9932360
    Abstract: Disclosed herein are “equipment-free” flow-through assay devices based on patterned porous media, methods of making same, and methods of using same. The porous, hydrophilic media are patterned with hydrophobic barriers for performing assays on liquids.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: April 3, 2018
    Assignee: The Penn State Research Foundation
    Inventors: Scott Thomas Phillips, Gregory Gerald Lewis, Jessica Sloane Robbins
  • Convenient process for the preparation of statins
    Patent number: 9932361
    Abstract: Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: April 3, 2018
    Inventors: Ottorino De Lucchi, Stefano Tartaggia, Clark Ferrari, Marco Galvagni, Marta Pontini, Stefano Fogal, Riccardo Motterle, Rosa Maria Moreno, Alex Comely
  • Processes for the preparation of ruthenium or osmium complexes comprising P and N donor ligands
    Patent number: 9932362
    Abstract: An improved processes for the preparation of ruthenium or osmium complexes including P and N donor ligands, in particular, ruthenium complexes.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 3, 2018
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Sarah Facchetti, Hans Nedden
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9932363
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 3, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA
    Patent number: 9932364
    Abstract: Antisense nucleic acid molecules, such as ribozymes, shRNA and siRNA, targeting the Gag region of HIV-1 open reading frame, and uses thereof for inhibiting HIV-1 replication and infection, are disclosed. The antisense nucleic acid molecules more specifically target a sequence corresponding to about nucleotide 1495 to about nucleotide 1526, or nucleotide 1497 to about nucleotide 1521, of HIV-1 clone pNL4-3.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: April 3, 2018
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Anne Gatignol, Robert Scarborough
  • Protein labeling with cyanobenzothiazole conjugates
    Patent number: 9932365
    Abstract: The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula I. For example, the invention provides methods for labeling the N-terminus of a protein that terminates with a cysteine residue. The invention also provides methods for isolating an N-terminally labeled protein and methods for detecting an N-terminally labeled protein.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 3, 2018
    Assignee: PROMEGA CORPORATION
    Inventors: Jessica Kelts, Poncho Meisenheimer, John Shultz
  • Method for using nanoparticles as nucleation agents for the crystallization of proteins
    Patent number: 9932366
    Abstract: The present invention relates to a method for the crystallization of protein using nanoparticles as nucleation agents. Precisely, the inventors performed the crystallization of such proteins as Bacillus subtilis YesR, chicken egg white lysozyme, bovine serum albumin, Alicyclobacillus acidocaldarius acetyl-CoA carboxylase, and Listeria monocytogenes hypothetical protein which have his-tag at amino terminal by using gold nanoparticles in diverse sizes and shapes in the presence of Ni2+ ions. As a result, it was confirmed that the chance of successful crystallization was higher with the gold nanoparticles than without the gold nanoparticles and the various crystallization conditions were successfully screened. Therefore, the method for inducing nucleation of the invention can be advantageously used for the disclosure of protein structure by increasing the chance of successful crystallization of protein.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 3, 2018
    Assignee: UNIVERSITY OF SEOUL INDUSTRY COOPERATION FOUNDATION
    Inventors: Jungwoo Choe, Inhee Choi
  • Modification of polypeptides
    Patent number: 9932367
    Abstract: The invention provides a method for conjugating a peptide displayed on a genetic display system to a molecular scaffold performed on an ion exchange resin.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: April 3, 2018
    Assignee: BICYCLERD LIMITED
    Inventors: Catherine Stace, Edward Walker
  • Peptides for the stimulation of collagen formation
    Patent number: 9932368
    Abstract: The present invention relates to a compound of formula (I) (R1-Arg-Gly-Asp-Gly-Ala-Asn-Pro-Asn-Ala-Ala-Gly-R2), formula II (R5-Arg-Gly-Asp-Gly-Pro-Gln-Gly-Pro-Gln-R6), or formula III (R9-Trp-Arg-Phe-Gln-Trp-Gln-Phe-Glu-Gln-R10), and to compositions comprising a compound of formulas I, II or III, as well as the use of said compounds and/or said compositions in the cosmetic treatment of skin and/or hair, and to the use thereof for inducing the formation of collagen.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: April 3, 2018
    Assignee: INFINITEC ACTIVOS S.L.
    Inventors: Fernando Albericio Palomera, Gerardo Alexis Acosta Crespo
  • Thermosensitive, bioactive biopolymer and associated method of cell harvesting
    Patent number: 9932369
    Abstract: The present invention relates to a biopolymer and a cell-harvesting scaffold comprising same, as well as the associated cell-harvesting method that allows said harvesting to be performed in a simple and effective manner by reducing the culture temperature. The present invention also relates to a method for synthesizing said biopolymer.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 3, 2018
    Assignee: UNIVERSIDAD DE VALLADOLID
    Inventors: Jose Carlos Rodriguez-Cabello, Francisco Javier Arias Vallejo, Matilde Alonso Rodrigo, Mercedes Santos Garcia, Maria Pierna Alvarez
  • Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers
    Patent number: 9932370
    Abstract: The invention features isolated human immunodeficiency virus (HIV) envelope (Env) trimers, in which the amino acid sequence of the Env polypeptides is optimized to stabilize formation of the trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 3, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Joseph Patrick Nkolola
  • Promiscuous HPV16-derived T helper epitopes for immunotherapy
    Patent number: 9932371
    Abstract: The present invention relates to novel amino acid sequences of peptides derived from HPV16 that are able to bind to MHC complexes of class II, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and T-cells, based on said epitopes.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: April 3, 2018
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Agnieszka Grabowska, Angelika Riemer
  • Designer peptide-based PCV2 vaccine
    Patent number: 9932372
    Abstract: Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: April 3, 2018
    Assignee: UNITED BIOMEDICAL, INC.
    Inventors: Chang Yi Wang, Wen-Jiun Peng
  • Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
    Patent number: 9932373
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: April 3, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Lisa L. Herron-Olson, Drew M. Catron
  • Clostridium difficile polypeptides as vaccine
    Patent number: 9932374
    Abstract: The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating a C. difficile infection in a mammal.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: April 3, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Cesira Galeotti, Rosanna Leuzzi, Mariagrazia Pizza, Maria Scarselli, Meera Unnikrishnan, Manuele Martinelli
  • Targeting of chondroitin sulfate glycans
    Patent number: 9932375
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 3, 2018
    Assignee: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • Analogues of temporin-SHa and uses thereof
    Patent number: 9932376
    Abstract: The present invention relates to novel antimicrobial peptides, pharmaceutical compositions comprising said peptides, and the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 3, 2018
    Assignees: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Ali Ladram, Denis Sereno, Thierry Foulon, Bruno Oury